Brought to you by:
TAMBE and TBE: Evolving experiences and piecing together channels of inquiry
New findings chronicling progress with both the Gore Excluder thoracoabdominal branch endoprosthesis (TAMBE)— approved by the Food and Drug Administration (FDA) last year—and Gore Tag thoracic branch endoprosthesis (TBE), which recently acquired a new indication for use in aortic zones…
Gore Tag thoracic branch endoprosthesis receives expanded FDA approval for endovascular aortic arch repair
Gore has announced that the Gore Tag thoracic branch endoprosthesis (TBE) is now approved by the Food and Drug Administration (FDA) for use in Zones 0 and 1, expanding its indication for the endovascular repair of lesions in the aortic…
SCVS 2025: TBE device provides ‘safer’ option than TEVAR for blunt thoracic injuries in setting of zone 2 coverage
Use of the Gore Tag thoracic branch endoprosthesis (TBE) “offers a safer alternative” to traditional thoracic endovascular aortic repair (TEVAR) with left subclavian artery (LSA) coverage in blunt thoracic aortic injury (BTAI) requiring zone 2 coverage for zone 2 or…